Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Merck & Co., Inc. — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $53.65, while Merck & Co., Inc. trades at $123.59 (market cap $305.12B). The key difference: Merck & Co., Inc. pays a 2.75% dividend while YieldMax AMD Option Income Strategy ETF pays none. Which is the better fit depends on your goals.
| AMDY | MRK | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $129.52 |
52-Week Low | $29.80 | $77.60 |
Market Cap | — | $305.12B |
Enterprise Value | — | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $55.56, up 2.04% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong weekly dividend distributions but lacks traditional valuation metrics. Recent news highlights its high-yield strategy and associated risks of NAV erosion, with support at $54 and resistance at $56.
The outlook is mixed: high income appeals, but structural risks and analyst caution suggest volatility. Investors must weigh yield sustainability against potential capital depreciation, with entry timing critical for long-term viability.
Merck (MRK) trades at $123.585, up 0.04% on the day, with a bullish technical signal and strong institutional interest. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a favorable analyst consensus.
The outlook for MRK is positive, supported by earnings beats, a high analyst buy rating (67.57%), and a consensus price target of $135.14. Key risks include rising debt levels and potential regulatory pressures, but the stock's solid fundamentals and acquisition strategy present a compelling opportunity for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
